Dong-A ST files IND for Phase 1 clinical trial of ADC candidate for cancer

CAR-T Digest - August 2020

24 June 2025: Dong-A ST files IND for Phase 1 clinical trial of ADC candidate for cancer

Dong-A ST’s ADC subsidiary, Aptis, has submitted an IND application in South Korea for DA-3501 (AT-211), a candidate targeting difficult-to-treat solid tumors such as gastric and pancreatic cancers, to initiate Phase 1 trials
DA-3501 targets Claudin 18.2, a protein overexpressed in certain cancer cells, and is designed to enhance efficacy in treating gastric and pancreatic cancers
The ADC utilizes Aptis’s proprietary AbClick platform technology, which is expected to provide enhanced selectivity and safety over existing ADCs
The submission marks a key milestone in Dong-A ST’s move into next-generation oncology therapeutics, with Aptis set to progress DA-3501 through early-phase development in South Korea